XML 28 R5.htm IDEA: XBRL DOCUMENT v3.3.1.900
Interim Condensed Consolidated Statements of Capital Equity (Deficit) - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Shares to be Issued [Member]
Accumulated Deficit [Member]
Accumulated other comprehensive income (loss)[Member]
Total
Beginning Balance at Jan. 22, 2013 $ 0          
Shares issued for cash, intellectual property and services $ 8,510,000         $ 8,510,000
Shares issued for cash, intellectual property and services (Shares) 32,070,052          
Net loss for the period       $ (8,517,850)   (8,517,850)
Ending Balance at Mar. 31, 2013 $ 8,510,000     (8,517,850)   (7,850)
Ending Balance (Shares) at Mar. 31, 2013 32,070,052          
Stock-based compensation on 654,481 options granted   $ 173,873       173,873
Stock-based compensation on 2,300,000 options granted   560,082       560,082
Stock-based compensation on 275,550 options granted   73,202       73,202
Share issuance cost           0
Net loss for the period       (1,067,284)   (1,067,284)
Ending Balance at Mar. 31, 2014 $ 8,510,000 807,157   (9,585,134)   (267,977)
Ending Balance (Shares) at Mar. 31, 2014 32,070,052          
Stock-based compensation on 2,300,000 options granted   50,303       50,303
Shares issued to consultant for option exercise 1 $ 717         717
Shares issued to consultant for option exercise 1 (Shares) 2,300,000          
Shares issued to consultant for option exercise 2 $ 290         290
Shares issued to consultant for option exercise 2 (Shares) 930,031          
Fair value of options allocated to share capital on exercise of options $ 857,460 (857,460)        
Recapitalization of Helius Medical Technologies, Inc.   162,890       162,890
Recapitalization of Helius Medical Technologies, Inc. (Shares) 10,000,000          
Issuance of common stock for private placement $ 6,437,041 578,961       7,016,002
Issuance of common stock for private placement (Shares) 15,240,000          
Share issuance cost $ (447,515) 67,709       (379,806)
Beneficial conversion feature   176,488       176,488
Stock-based compensation on 3,370,000 options granted   1,227,724       1,227,724
Conversion of debenture $ 1,000,100         1,000,100
Conversion of debenture (Shares) 2,564,705          
Stock-based compensation on 400,000 options granted   135,564       135,564
Stock-based compensation on 100,000 options granted 1   74,190       74,190
Stock-based compensation on 100,000 options granted 2   43,229       43,229
Stock-based compensation on 100,000 options granted 3   41,987       41,987
Fair value of vested non-employee options reallocated to derivative liability   (74,190)       (74,190)
Private placement proceeds     $ 39,545     39,545
Net loss for the period       (9,838,317)   (9,838,317)
Translation adjustments         $ (971,640) (971,640)
Ending Balance at Mar. 31, 2015 $ 16,358,093 $ 2,434,552 $ 39,545 $ (19,423,451) $ (971,640) $ (1,562,901)
Ending Balance (Shares) at Mar. 31, 2015 63,104,788